DENVER, CO, August 31, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Carl H. June, M.D. to its Scientific Advisory Board.
“We are delighted to have the opportunity to welcome Dr. June’s expertise in immunology and cancer immunotherapy to our Scientific Advisory Board as we continue to advance our therapeutic programs,” said Dr. Timothy C. Rodell, CEO of GlobeImmune. Dr. June joins existing advisors Teresa Brentnall, M.D., Paul Bunn, M.D., Francis Chisari, M.D., Edgar Engleman, M.D., Edward Mocarski, Ph.D., Robert (Chip) Schooley, M.D., Alan Venook, M.D., and Bruce Walker, M.D.
Dr. June is currently Director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania, and is an Investigator of the Abramson Family Cancer Research Institute. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in Internal Medicine and Medical Oncology. He founded the Immune Cell Biology Program and was head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995. He rose to Professor in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda, Maryland before assuming his current position as of February 1, 1999. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy.
About GlobeImmune, Inc.
GlobeImmune, Inc. is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of cancer and infectious diseases. The Company’s lead product series, GI-4000 for the treatment of cancers of the lung and gastrointestinal tract, is currently in Phase 1 clinical trials. The Company initiated a Phase 1b trial for its second product, GI-5005, a Tarmogen for the treatment of chronic hepatitis C infection in July 2005.
Tarmogens are whole, heat-killed recombinant Saccharomyces cerevisiae yeast genetically modified to express one or more protein antigens that stimulate the immune system against diseased cells. Tarmogens are avidly taken up by the cells that activate the immune system called antigen presenting cells, to stimulate a T cell response against the desired target(s). GlobeImmune’s patented Tarmogen platform has a number of advantages over current approaches including that Tarmogens generate potent T cell immune responses, are not neutralized by the immune system, can be rapidly engineered and are simple to manufacture.
For additional information, please visit the company’s website at http://www.globeimmune.com/.